Cellectar Biosciences (CLRB) Stock Overview
A clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CLRB Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cellectar Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.09 |
| 52 Week High | US$20.59 |
| 52 Week Low | US$2.43 |
| Beta | 0.43 |
| 1 Month Change | 5.82% |
| 3 Month Change | -0.96% |
| 1 Year Change | -59.69% |
| 3 Year Change | -92.90% |
| 5 Year Change | -99.32% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Late Stage Radiopharmaceutical Catalyst And Global IP Platform Will Transform Future Cancer Treatment Prospects
Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies based on its phospholipid drug conjugate platform for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?
Regulatory And Funding Risks Will Test Radiopharmaceutical Pipeline Yet Long Term Prospects Will Improve
Catalysts About Cellectar Biosciences Cellectar Biosciences is a radiopharmaceutical company focused on phospholipid drug conjugates for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?
Future Radiopharmaceutical Pipeline Expansion Will Support A Stronger Long Term Outlook
Catalysts About Cellectar Biosciences Cellectar Biosciences develops targeted radiopharmaceutical therapies for difficult to treat cancers using its proprietary phospholipid drug conjugate platform. What are the underlying business or industry changes driving this perspective?We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Summary Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug. Read the full article on Seeking AlphaHere's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Cellectar Biosciences press release (NASDAQ:CLRB): Q2 GAAP EPS of -$1.22 misses by $0.19. As of June 30, 2022, the company had cash and cash equivalents of $24.8 million, compared to $35.7 million as of December 31, 2021.Cellectar announces reverse stock split
Cellectar Biosciences (NASDAQ:CLRB) said it is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one new Common Share for every 10 currently outstanding. As of Thursday, the company will have about 6.1M shares outstanding. The new common shares will be effective for trading purposes as of the commencement of trading on Friday, July 22, and will trade under CUSIP number 15117F807. Stockholders who would otherwise hold a fractional share will receive a cash payment in lieu of the fractional share.We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Shareholder Returns
| CLRB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | -1.8% | -0.3% |
| 1Y | -59.7% | 32.7% | 24.1% |
Return vs Industry: CLRB underperformed the US Biotechs industry which returned 32.7% over the past year.
Return vs Market: CLRB underperformed the US Market which returned 24.1% over the past year.
Price Volatility
| CLRB volatility | |
|---|---|
| CLRB Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CLRB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CLRB's weekly volatility has decreased from 16% to 11% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 11 | Jim Caruso | www.cellectar.com |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program.
Cellectar Biosciences, Inc. Fundamentals Summary
| CLRB fundamental statistics | |
|---|---|
| Market cap | US$13.10m |
| Earnings (TTM) | -US$20.84m |
| Revenue (TTM) | n/a |
Is CLRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLRB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.84m |
| Earnings | -US$20.84m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.92 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CLRB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/18 21:15 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellectar Biosciences, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Keith Markey | Griffin Securities |
| Kevin DeGeeter | Ladenburg Thalmann & Company |